These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38173401)

  • 1. We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?
    Grebely J; Matthews S; Causer LM; Feld JJ; Cunningham P; Dore GJ; Applegate TL
    Expert Rev Mol Diagn; 2024 Mar; 24(3):177-191. PubMed ID: 38173401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.
    Grebely J; Applegate TL; Cunningham P; Feld JJ
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1109-1115. PubMed ID: 29088981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
    Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal.
    Duchesne L; Hejblum G; Toure Kane NC; Njouom R; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
    Int J Drug Policy; 2020 Jan; 75():102613. PubMed ID: 31786434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
    Latham NH; Pedrana A; Doyle JS; Howell J; Williams B; Higgs P; Thompson AJ; Hellard ME
    J Viral Hepat; 2019 Jul; 26(7):919-922. PubMed ID: 30801881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Hepatitis C Virus (HCV) Diagnostic Tools Are Needed to Advance Diagnosis of Current HCV Infection in Outreach Settings and in a Nonclinical Setting?
    Page K; Feinberg J
    J Infect Dis; 2024 May; 229(Supplement_3):S328-S333. PubMed ID: 37739782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination.
    Kapadia SN; Jordan AE; Eckhardt BJ; Perlman DC
    Clin Infect Dis; 2024 May; 78(5):1235-1239. PubMed ID: 37633653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis.
    Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL
    J Infect Dis; 2020 Jun; 221(12):2043-2049. PubMed ID: 31993636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.
    Blackburn NA; Patel RC; Zibbell JE
    Public Health Rep; 2016; 131 Suppl 2(Suppl 2):91-7. PubMed ID: 27168667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
    J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA.
    Smookler D; Vanderhoff A; Biondi MJ; Valencia J; Ryan P; Karkada J; Hong R; Sattar I; Mandel E; Gjevori M; Casey J; Fletcher D; Shah H; Hansen BE; Capraru C; Janssen HLA; Lazarus JV; Feld JJ
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1451-1458.e4. PubMed ID: 32763480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of hepatitis C virus RNA detection using capillary blood by finger prick (GenXpert system)-Hepatitis C fingerprick study.
    Bielen R; Koc ÖM; Busschots D; Verrando R; Nevens F; Robaeys G
    J Viral Hepat; 2020 Jul; 27(7):709-714. PubMed ID: 32106345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
    Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
    Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.